Thomas Eigentler
Eberhard Karls Universität Tübingen
H-index: 65
Europe-Germany
Top articles of Thomas Eigentler
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first … | Plos one | Felix Peisen Annika Gerken Isabel Dahm Konstantin Nikolaou Thomas Eigentler | 2024/1/5 |
Melanoma of the central nervous system based on neurocutaneous melanocytosis in childhood: A rare but fatal condition | Pediatric Blood & Cancer | Michael Abele Stephan Forchhammer Thomas K Eigentler Aryana Popescu Linda Maschke | 2024/4 |
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma | Journal for immunotherapy of cancer | Danny Rischin Brett GM Hughes Nicole Basset-Séguin Dirk Schadendorf Samantha Bowyer | 2024 |
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with … | Journal of the American Academy of Dermatology | Nikolaus B Wagner Sarah M Knierim Felix Luttermann Gisela Metzler Amir S Yazdi | 2024/4/1 |
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy | European Journal of Cancer | Nikolaus B Wagner Max M Lenders Kathrin Kühl Lydia Reinhardt Milena Fuchß | 2024/1/1 |
The side effect registry immuno-oncology (SERIO)–A tool for systematic analysis of immunotherapy-induced side effects | European Journal of Cancer | Carolin Ertl Theresa Ruf Dirk Mentzer Mingzi Kong Rafaela Kramer | 2024/3/1 |
Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia | Journal of the European Academy of Dermatology and Venereology | Julia Huynh Ulrike Leiter Claus Garbe Galina Shiderova Vincent Walter | 2024/1 |
Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation | Nature Cancer | Meri Rogava Tyler J Aprati Wei-Yu Chi Johannes C Melms Clemens Hug | 2024/1/29 |
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors | European Journal of Cancer | Theresa Ruf Rafaela Kramer Andrea Forschner Ulrike Leiter Friedegund Meier | 2024/5/1 |
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy | Journal of Experimental & Clinical Cancer Research | Francisco Meraz-Torres Heike Niessner Sarah Plöger Simon Riel Barbara Schörg | 2024/1/23 |
The KEYNOTE-630 Trial: A Phase 3 Study of Adjuvant Pembrolizumab in High-Risk Locally Advanced (LA) Cutaneous Squamous Cell Carcinoma (cSCC) | International Journal of Radiation Oncology, Biology, Physics | Michael Schenker Mikhail Klochikhin Dmitry Kirtbaya Laurent Mortier Martin Gschnell | 2024/4/1 |
Time to next treatment in primary cutaneous B cell lymphoma: experience on 98 patients | European Journal of Cancer | Rohat Cankaya Pit Leonard Kleiner Franz Hilke Rose Moritz Thomas Eigentler | 2023/9/1 |
UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescents | EBioMedicine | Alexandra Liebmann Jakob Admard Sorin Armeanu-Ebinger Hannah Wild Michael Abele | 2023/10/1 |
S3 guideline „actinic keratosis and cutaneous squamous cell carcinoma “–update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of … | JDDG: Journal der Deutschen Dermatologischen Gesellschaft | Ulrike Leiter Markus V Heppt Theresa Steeb Mareike Alter Teresa Amaral | 2023/11 |
Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915) | Journal of Clinical Oncology | Jeffrey S Weber Dirk Schadendorf Michele Del Vecchio James Larkin Victoria Atkinson | 2023/1/1 |
German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma”–Long version of the update 2023 | EJC Skin Cancer | Ulrike Leiter Markus V Heppt Theresa Steeb Mareike Alter Teresa Amaral | 2023/1/1 |
Real‐world outcomes using PD‐1 antibodies and BRAF+ MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland | Journal of the European Academy of Dermatology and Venereology | Katharina Schumann Cornelia Mauch Kai‐Christian Klespe Carmen Loquai Ulrike Nikfarjam | 2023/5 |
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600 … | European Journal of Cancer | E Livingstone H Gogas L Kandolf-Sekulovic F Meier TK Eigentler | 2023/9/1 |
Histopathologic abundance of pigmentation correlates with disease‐specific survival in malignant melanoma but is not independent of current AJCC pT stage | Pigment Cell & Melanoma Research | Valentin Aebischer Amar Abu‐Ghazaleh Gisela Metzler Lena Riedl Claus Garbe | 2023/11 |
Abstract PO-009: Phase 3 KEYNOTE-630 study of adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma | Clinical Cancer Research | Michael Schenker Mikhail Klochikhin Dmitry Kirtbaya Laurent Mortier Martin Gschnell | 2023/9/15 |
